Emerging Perspectives in Addiction Psychiatry
The Journal of Clinical Psychiatry August 3, 2023 DOI: 10.4088/jcp.muladx3048sho (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Addiction |
| Keywords | Psychotherapist |
| Citations | 1 |
| Key findings | A comprehensive, integrated public health approach is essential for treating substance use disorders, and psychedelic compounds show potential for treating addiction and related symptoms. |
Abstract
Despite their legality, alcohol and tobacco both have a well-documented potential for misuse and elevate users' likelihood for disease. Dependence on alcohol also contributes to opioid overdoses, which claim 130 lives every day. Although awareness of the opioid epidemic is rising broadly among health care professionals, a majority of Americans still do not receive adequate, FDA-approved medications for their addiction. Effective medications are available for alcohol use disorder and medications for opioid use disorder have validated benefits that justify their use. In recent years, psychedelic compounds have attracted interest among scientists for their potential to alter mood and cognition in beneficial manners. Already, some evidence supports the use of psilocybin in alleviating symptoms of depression and anxiety; psychedelic compounds also have potential as alcohol use disorder treatments and may help reduce symptoms tied to opioid withdrawal. Because substance use disorders can culminate in death, a comprehensive, integrated, public health approach to the treatment of people with substance use disorders is essential.
Comparable studies
Other narrative reviews on addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| Mindfulness meditation–based pain relief: a mechanistic account | 2016 | Review | |
| Psychedelics as anti-inflammatory agents Animal models and cellular studies | 2018 | Review | |
| A narrative review of yoga and mindfulness as complementary therapies for addiction. | 2013 | Review | |
| The neuropsychopharmacology of cannabis: A review of human imaging studies | 2018 | Review |
Citations in the library
Cites 3
- Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial Journal of Psychopharmacology March 20, 2023
- Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Current Drug Abuse Reviews 2014
- Racial Disparities in Access to Psychedelic Treatments and Inclusion in Research Trials Psychiatric Annals December 1, 2022